Call for Round Table Discussion Leaders

The organizing committee invites you to propose and volunteer to lead a round table luncheon discussion at the ***DIA Oligonucleotide-Based Therapeutics Conference*** to be held **October 25-27** at the **Bethesda North Marriott Hotel, North Bethesda, MD.**

Proposals must be submitted electronically via selecting the following online form or coping/pasting the link into your web browser:

Online Submission Form

The deadline for submission is **August 25, 2017** and selection will be made by September 5, 2017. The Roundtable luncheon will be held on October 26, 2017 from 11:45 AM – 1:00 PM ET.

General guidelines for Round Table Discussions:

- Round table discussions are being held during a 75 minute luncheon period. The first 15-20 minutes will be allocated to attendees for gathering their lunch and finding their table assignment. The discussion period will be approximately 55-60 minutes.
- Round tables are set up for a maximum of 8-10 participants at each table.
- Participants (attendees) will be asked to complete an online survey in advance of the program to select a table. Those who have not selected a table in advance will be accommodated on-site on a first-come, first served basis.
- **All round table discussions must be noncommercial and scientific in nature and may not be used as a marketing opportunity.** Any mention of drug products must be limited to generic names. Please refer to the DIA Policy Concerning Promotion of Products and Services from the Podium at DIA-Sponsored Activities.

When submitting your proposal to lead a Round Table discussion we will ask for:

1. Your name
2. Contact information
3. The round table discussion title *(note this can be tentative)*
4. A general theme/topic *(examples listed below)*
5. A short (2-3 sentences) description of the round table topic with 2-3 questions you plan to discuss

Potential roundtable luncheon discussion topics may include (but are not limited to) the following list broad topics:

- 21st Century Cures
- PDUFA VI
- Immuno/Oncology
- Real World Evidence
- Global Regulatory Progress
- Assay Development and Optimization
- Clinical Pharmacology,including Oligonucleotide
- ADME
    - Clinical Safety
    - Formulations
- Impurities
- Manufacturing
- Nonclinical Efficacy Models
- Toxicology, including updates in oligo toxicology (clinical and nonclinical)
- Novel Mechanisms for Intervention
- Novel Oligonucleotide Therapeutics
- Oligonucleotide Conjugation and Tissue Targeting
- Regulatory affairs, including Oligonucleotide Regulatory Guidance
- Oligonucleotide Therapeutics for:
    - Rare Diseases
    - Immunoncology
    - Metabolic diseases
    - Neuromuscular Conditions
- Targeting and Delivery, including Target Identification Screening
- Methods (Discovery)
    - Translational Experience

Each of these broad topics may have subtopics that you wish to expand upon in your luncheon dialogue - *feel free to be creative.*

If selected, you will be responsible for all costs (e.g., registration, travel, lodging). Also note that the submission form does not allow for updates. If you need to update your submission, please completely resubmit your proposal. There is a field at the end of the form to indicate that it is a resubmission.
Notifications are scheduled for the week of September 5.

Please send questions and inquiries to
Meredith O. Kaganovskiy, CMP
Project Manager, Meeting Operations
DIA
Email: Meredith.Kaganovskiy@DIAglobal.org

We look forward to receiving your proposals **by August 25,** and your participation in this conference.

Thank you,
The DIA Oligonucleotide-based Therapeutics Conference Program Committee

PROGRAM CO-CHAIRS

James Thompson, PhD
Head, CMC Project Management
Moderna Therapeutics

James Wild, PhD
Pharmacologist
CDER, FDA

PROGRAM COMMITTEE

Robert T. Dorsam, PhD
Pharmacology and Toxicology Team Leader, OGD
CDER, FDA

Paul C. Brown, PhD
ODE Associate Director for Pharmacology and Toxicology, OND
CDER, FDA

Daniel Capaldi, PhD
Vice President
Analytical and Process Development
Ionis Pharmaceuticals, Inc

Xuan Chi, PhD
Pharmacology/Toxicology Reviewer, Division of Cardiovascular and Renal Products, OND
CDER, FDA

Scott Henry, PhD, DABT
Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc

Aimee L. Jackson, PhD
Director of Target Development
miRagen Therapeutics

Arthur M. Krieg, MD
President and CEO
Checkmate Pharmaceuticals

Art A. Levin, PhD
Executive VP Research and Development
Avidity NanoMedicines

Jennifer Marlowe, PhD
Group Head
Biochemical, Molecular and Cellular Toxicology
Novartis Institutes for Biomedical Research, Inc.

Saraswathy V. Nochur, PhD, MSc
Senior Vice President Regulatory Affairs and QA
Alnylam Pharmaceuticals, Inc.

Emily J. Place
Pharmacologist, Office of New Drugs
CDER, FDA

Ramesh Raghavachari, PhD
Chief
Branch I, DPMA1, OLDP, OPQ
CDER, FDA

Rosanne Seguin, PhD
Professional Associate
McGill University

Kim Tyndall
Director of CMC Regulatory Affairs
GlaxoSmithKline